TNGX NASDAQ
Tango Therapeutics, Inc.
1W: -9.3%
1M: -5.8%
3M: -11.4%
YTD: +156.3%
1Y: +205.2%
3Y: +203.6%
5Y: +79.0%
$22.89
+0.69 (+3.13%)
Pre-Market: $22.83 (-0.06, -0.26%)
Weekly Expected Move ±12.7%
$17
$20
$23
$26
$29
Credit Risk of going bust: lower than 53% of companies Debt: 0.8% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the middle of the pack, about 1 in 580 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.04 (down 99.8%), Tango Therapeutics, Inc. would be worth roughly what it owes.
Total debt $32.0M against a stock market value of $3.86B.
Distance to default 5.39 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $17.5M (short-term plus half of long-term), stock volatility 93.4%; Altman Z'' 25.07. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.04 (down 99.8%), Tango Therapeutics, Inc. would be worth roughly what it owes.
Total debt $32.0M against a stock market value of $3.86B.
Distance to default 5.39 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $17.5M (short-term plus half of long-term), stock volatility 93.4%; Altman Z'' 25.07. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
6 relationships6
As Filer
counterparties named
0
As Counterparty
mentioned by others
4
Rel. Types
2021-04-14
Earliest Filing
2025-11-21
Latest Filing
partner: 3
acquirer: 1
target: 1
investor: 1
Counterparties (Filed by TNGX)
6 relationshipsCompanies named in TNGX's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Leerink Partners LLC | — | partner | Sales agent for ATM Offering | 2025-11-21 | View |
| Jefferies LLC | JEF | partner | Former sales agent for 2022 ATM Program | 2025-11-21 | View |
| BCTG Acquisition Corp. | BCTG | acquirer | Acquired Tango Therapeutics, Inc. in a business combination consummated on August 10, 2021. | 2021-08-13 | View |
| Gilead Sciences Inc. | GILD | partner | Partnered with Tango Therapeutics, Inc. under a collaboration agreement expanded in August 2020 to identify and develop | 2021-08-13 | View |
| Tango Therapeutics, Inc. | TNGX | target | Target company in the business combination with BCTG Acquisition Corp. | 2021-04-14 | View |
| BCTG Holdings, LLC | — | investor | Sponsor of BCTG that entered into a support agreement and has option to increase cash investment. | 2021-04-14 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-10-23 | Regulation FD; Other Events; Exhibits | View | |
| 2026-08-11 | Earnings Release; Exhibits | View | |
| 2026-08-11 | Other Events; Exhibits | View | |
| 2026-08-07 | Officer/Director Change; Regulation FD; Exhibits | View | |
| 2026-08-06 | Officer/Director Change | View | |
| 2026-06-23 | Officer/Director Change; Exhibits | View | |
| 2026-06-10 | Material Agreement; Exhibits | Agreement | View |
| 2026-06-08 | Regulation FD; Other Events; Exhibits | View | |
| 2026-06-04 | Shareholder Vote | View | |
| 2026-05-13 | Earnings Release; Officer/Director Change; Exhibits | View | |
| 2026-05-08 | Officer/Director Change; Exhibits | View | |
| 2026-04-15 | Officer/Director Change; Regulation FD; Exhibits | View | |
| 2026-03-05 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2026-01-08 | Results of Operations and Financial Condition; Departure/Election of Directors; Appointment of Offic | View | |
| 2026-01-05 | Departure/Election of Directors; Appointment of Officers; Financial Statements and Exhibits | View | |
| 2025-11-21 | Entry into Material Definitive Agreement; Termination of Material Definitive Agreement | Agreement | View |
| 2025-11-04 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-10-24 | Entry into Material Definitive Agreement; Unregistered Sales of Equity Securities; Financial Stateme | Agreement | View |
| 2025-10-23 | Results of Operations and Financial Condition; Other Events; Financial Statements and Exhibits | View | |
| 2025-08-25 | Departure/Election of Directors; Appointment of Officers | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR